SHL
$9.9BCF+
Sonic Healthcare
Pathology
Global pathology and radiology provider operating in Australia, US, UK, Germany, Switzerland, Belgium, Ireland
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.0M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$9.9B
Burn Rate
—
Dec 2025 4C
Shares Outstanding
494M
Pipeline Assets
3
Latest Insight(1)
13 Apr 2026substantial_holderChange in substantial holding
Changed·State Street Corporation and subsidiaries·8.41%
3M Price
SHL.ASX$20.080-13.0% 3M
Low $19.480High $23.406
Pipeline Assets (3)
Pathology servicesClinical laboratory diagnostics
ApprovedRadiology servicesDiagnostic imaging services
ApprovedClinical trials servicesCentral laboratory for clinical trials
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
2 transactionsLast 90dNo Activity
Buys0
Sells0
PERFORMANCE RIGHTSChristopher David Wilksopen_in_new
02026-03-04
PERFORMANCE RIGHTSChristopher David Wilksopen_in_new
2026-03-04
Substantial Holders (5%+ threshold)
1 noticearrow_drop_downState Street Corporation and subsidiaries
8.41%2026-04-13
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
11 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
J Interprof Care2026-04· Pathology services
Am J Clin Pathol2026-04· Pathology services
J Forensic Leg Med2026-04· Pathology services
Catalysts (2)
FY2026 full-year results
UpcomingConfirmedremoveMed20 Aug 2026
LADR synergy realisation — first full year
UpcomingExpectedremoveMed31 Dec 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| FY2026 full-year results H1 revenue A$5.445B, EBITDA A$907M. Market expects further margin improvement | other | Confirmed | removeMed |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.